161 related articles for article (PubMed ID: 3063116)
1. Normal and abnormal regulation of 1,25-(OH)2D synthesis.
Breslau NA
Am J Med Sci; 1988 Dec; 296(6):417-25. PubMed ID: 3063116
[TBL] [Abstract][Full Text] [Related]
2. The role of insulin in the stimulation of renal 1,25-dihydroxyvitamin D synthesis by parathyroid hormone in rats.
Ikeda K; Matsumoto T; Morita K; Yamato H; Takahashi H; Ezawa I; Ogata E
Endocrinology; 1987 Nov; 121(5):1721-6. PubMed ID: 3311717
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in pediatric metabolic bone disease: the consequences of altered phosphate homeostasis in renal insufficiency and hypophosphatemic vitamin D-resistant rickets.
Pettifor JM
Bone Miner; 1990 Jun; 9(3):199-214. PubMed ID: 2163713
[TBL] [Abstract][Full Text] [Related]
4. 1,25-Dihydroxyvitamin D production after stimulation with synthetic human parathyroid hormone (1-34) in hypoparathyroid and renal tubular disorders.
Yasuda T; Nakajima H
Endocrinol Jpn; 1984 Aug; 31(4):407-15. PubMed ID: 6097438
[TBL] [Abstract][Full Text] [Related]
5. Regulation of 1,25 (OH)2D synthesis in hypoparathyroidism and pseudohypoparathyroidism.
Breslau NA; Weinstock RS
Am J Physiol; 1988 Nov; 255(5 Pt 1):E730-6. PubMed ID: 2847540
[TBL] [Abstract][Full Text] [Related]
6. Correlations of serum concentrations of 1,25-dihydroxyvitamin D, phosphorus, and parathyroid hormone in tumoral calcinosis.
Lyles KW; Halsey DL; Friedman NE; Lobaugh B
J Clin Endocrinol Metab; 1988 Jul; 67(1):88-92. PubMed ID: 3379139
[TBL] [Abstract][Full Text] [Related]
7. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure.
Pitts TO; Piraino BH; Mitro R; Chen TC; Segre GV; Greenberg A; Puschett JB
J Clin Endocrinol Metab; 1988 Nov; 67(5):876-81. PubMed ID: 3182962
[TBL] [Abstract][Full Text] [Related]
8. Hyperphosphatemic tumoral calcinosis: effects of phosphate depletion on vitamin D metabolism, and of acute hypocalcemia on parathyroid hormone secretion and action.
Lufkin EG; Kumar R; Heath H
J Clin Endocrinol Metab; 1983 Jun; 56(6):1319-22. PubMed ID: 6687726
[TBL] [Abstract][Full Text] [Related]
9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
10. Main endocrine modulators of vitamin D hydroxylases in human pathophysiology.
Caniggia A; Lorè F; di Cairano G; Nuti R
J Steroid Biochem; 1987; 27(4-6):815-24. PubMed ID: 3320561
[TBL] [Abstract][Full Text] [Related]
11. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D status regulates 25-hydroxyvitamin D3-1 alpha-hydroxylase and its responsiveness to parathyroid hormone in the chick.
Booth BE; Tsai HC; Morris RC
J Clin Invest; 1985 Jan; 75(1):155-61. PubMed ID: 4038405
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D metabolites in renal insufficiency and other vitamin D disorders of children.
Chesney RW; Hamstra AJ; Phelps M; DeLuca HF
Kidney Int Suppl; 1983 Nov; 15():S63-9. PubMed ID: 6584678
[TBL] [Abstract][Full Text] [Related]
14. Demonstration of a lack of change in serum 1 alpha,25-dihydroxyvitamin D in response to parathyroid extract in pseudohypoparathyroidism.
Lambert PW; Hollis BW; Bell NH; Epstein S
J Clin Invest; 1980 Oct; 66(4):782-91. PubMed ID: 7419719
[TBL] [Abstract][Full Text] [Related]
15. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.
Portale AA; Booth BE; Halloran BP; Morris RC
J Clin Invest; 1984 Jun; 73(6):1580-9. PubMed ID: 6547151
[TBL] [Abstract][Full Text] [Related]
16. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part IV of IV parts: The state of the bones in uremic hyperaparathyroidism--the mechanisms of skeletal resistance to PTH in renal failure and pseudohypoparathyroidism and the role of PTH in osteoporosis, osteopetrosis, and osteofluorosis.
Parfitt AM
Metabolism; 1976 Oct; 25(10):1157-88. PubMed ID: 787723
[TBL] [Abstract][Full Text] [Related]
17. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.
Schömig M; Ritz E
Nephrol Dial Transplant; 2000; 15 Suppl 5():18-24. PubMed ID: 11073270
[TBL] [Abstract][Full Text] [Related]
18. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis.
Haug CJ; Aukrust P; Haug E; Mørkrid L; Müller F; Frøland SS
J Clin Endocrinol Metab; 1998 Nov; 83(11):3832-8. PubMed ID: 9814454
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D physiology.
Lips P
Prog Biophys Mol Biol; 2006 Sep; 92(1):4-8. PubMed ID: 16563471
[TBL] [Abstract][Full Text] [Related]
20. The development of pseudohypoparathyroidism. Involvement of progressively increasing serum parathyroid hormone concentrations, increased 1,25-dihydroxyvitamin D concentrations, and 'migratory' subcutaneous calcifications.
Tsang RC; Venkataraman P; Ho M; Steichen JJ; Whitsett J; Greer F
Am J Dis Child; 1984 Jul; 138(7):654-8. PubMed ID: 6328970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
